|
Fluorothiazinon |
|
Acinetobacter Chlamydia Klebsiella Pseudomonas Salmonella |
Biofilm TTSS (Type III secretion system) Biofilm TTSS (Type III secretion system) TTSS (SPI-1 encode); TTSS (SPI-2 encode) |
Preclinical (in vivo) Preclinical (in vivo) Preclinical (in vitro) Preclinical (in vivo) Phase II trial |
Bondareva NE, et al. 2022. J Antibiot (Tokyo) Zigangirova NA, et al. 2012. Acta Naturae; Koroleva EA, et al. 2015. Biomed Res Int; Zigangirova NA, et al. 2016. J Med Microbiol Tsarenko SV, et al. 2023. J Antibiot (Tokyo) Sheremet AB, et al. 2018. Biomed Res Int Nesterenko LN, et al. 2016. J Antibiot (Tokyo); Zigangirova NA, et al. 2021. J Antibiot (Tokyo) |
|
1-phenyl-3-[4-(phenylsulfamoyl)phenyl]thiourea |
Depiction based on curated SMILES
NH
S
N
H
O
HN
O
S
|
Escherichia Salmonella |
Regulation QseBC |
Preclinical (in vivo) Preclinical (in vivo) |
Rasko DA, et al. 2008. Science
|
|
({1-[2-(2-fluorophenyl)ethyl]-4-piperidinyl}methyl)methyl(3-thienylmethyl)amine |
Depiction based on curated SMILES
S
F
CH
3
N
N
|
Salmonella |
Biofilm |
Preclinical (in vivo) |
Woolard KJ, et al. 2022. Eur J Med Chem |
|
Dephostatin |
Depiction based on curated SMILES
CH
3
N
OH
HO
N
O
|
Salmonella |
PmrAB; SsrAB |
Preclinical (in vivo) |
Tsai CN, et al. 2020. Cell Chem Biol |
|
Compound 7b (internal name in literature) |
Depiction based on curated SMILES
N
Cl
Cl
CH
3
S
N
|
Salmonella |
Biofilm |
Preclinical (in vivo) |
Woolard KJ, et al. 2022. Eur J Med Chem |
|
Compound 7d (internal name in literature) |
Depiction based on curated SMILES
N
Br
Br
CH
3
S
N
|
Salmonella |
Biofilm |
Preclinical (in vivo) |
Woolard KJ, et al. 2022. Eur J Med Chem |
|
Compound 8j (internal name in literature) |
Depiction based on curated SMILES
CH
3
N
S
N
|
Salmonella |
Biofilm |
Preclinical (in vivo) |
Woolard KJ, et al. 2022. Eur J Med Chem |
|
(2Z,5Z)-5-(4-hydroxy-3,5-dimethoxybenzylidene)-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one |
Depiction based on curated SMILES
OH
CH
3
O
O
N
H
3
C
N
S
O
|
Salmonella Yersinia |
TTSS (SPI-1 encode) TTSS (Type III secretion system) |
Preclinical (in vitro) Preclinical (in vitro) |
Felise HB, et al. 2008. Cell Host Microbe
|
|
Mitoxantrone hydrochloride |
Depiction based on curated SMILES
O
OH
OH
HN
NH
OH
ClH
ClH
HN
HN
OH
O
|
Salmonella |
Invasion |
Preclinical (in vitro) |
Ridge Y, et al. 2018. J Appl Microbiol |
|
Sepantronium bromide |
Depiction based on curated SMILES
_
Br
N
N
O
CH
3
O
H
3
C
O
N
+
N
|
Escherichia Salmonella |
TTSS secreted effectors TTSS-2 secreted effectors |
Phase II trial Preclinical (in vitro) |
El Qaidi S, et al. 2018. Front Cell Infect Microbiol; Zhu C, et al. 2021. Pathogens
|
|
| | |